```html

Nephrogenic Diabetes Insipidus (NDI)

Overview

Nephrogenic Diabetes Insipidus (NDI) is a rare disorder in which the kidneys are unable to respond properly to the antidiuretic hormone (ADH, also called vasopressin). ADH normally signals the renal collecting ducts to re‑absorb water, concentrating urine. In NDI, this signaling pathway is disrupted, causing the kidneys to excrete large volumes of dilute urine while the thirst mechanism remains intact.

• Who it affects: Both males and females can develop NDI, but the most common form—X‑linked recessive NDI—primarily affects males. Autosomal‑dominant and autosomal‑recessive forms occur in both sexes.
• Prevalence: NDI is very uncommon, affecting roughly 1 in 250,000 to 1 in 500,000 live births worldwide. The X‑linked form accounts for about 90 % of cases.<sup>1</sup>
• Age of onset: Congenital forms present in infancy or early childhood, whereas acquired NDI may develop at any age, often after exposure to certain medications or kidney disease.

Symptoms

Symptoms stem from the inability to concentrate urine and the resulting chronic dehydration. The severity varies with the underlying cause and how well fluid intake compensates for urinary losses.

Classic triad

• Polyuria: Excretion of >3 L of urine per day in adults (often 10–15 L in children). The urine is low in specific gravity (<1.005).
• Polydipsia: Excessive thirst leading to a high fluid intake that may exceed 3 L per day.
• Nocturia: Waking multiple times nightly to urinate.

Additional clinical features

• Dry mouth or cracked lips.
• Failure to thrive or poor weight gain in infants.
• Irritability or lethargy due to fluctuating plasma osmolality.
• Electrolyte disturbances (hypernatremia, hyperchloremia).
• Dehydration signs: decreased skin turgor, sunken eyes, orthostatic hypotension.
• In severe cases, seizures or coma from extreme hypernatremia.

Causes and Risk Factors

NDI can be divided into congenital (genetic) and acquired (environmental or disease‑related) categories.

Congenital (Genetic) Forms

1. X‑linked recessive NDI (AVPR2 gene): Mutations in the vasopressin‑2 receptor gene on chromosome Xq28. >90 % of congenital cases.
2. Autosomal‑dominant NDI (AQP2 gene): Mutations in the aquaporin‑2 water‑channel gene; leads to a dominant‑negative effect.
3. Autosomal‑recessive NDI (AQP2 gene): Biallelic loss‑of‑function mutations causing severe early‑onset disease.

Acquired Forms

• Medications: Chronic lithium therapy (used for bipolar disorder) is the most common cause; also demeclocycline, foscarnet, and amphotericin B.<sup>2</sup>
• Kidney disease: Chronic renal failure, polycystic kidney disease, or interstitial nephritis can impair ADH response.
• Electrolyte abnormalities: Hypercalcemia and hypokalemia can reduce collecting‑duct sensitivity to ADH.
• Hormonal disturbances: High levels of glucocorticoids or severe hyperthyroidism may contribute.

Risk Factors

• Family history of congenital NDI.
• Long‑term lithium use (especially >5 years, >900 mg/day).
• Underlying chronic kidney disease.
• Pregnancy‑related hypercalcemia (rare, usually transient).

Diagnosis

Diagnosing NDI involves confirming that polyuria is not due to other causes and that the kidneys are unresponsive to ADH.

1. Clinical assessment: Detailed history (onset, fluid intake, medications), physical exam for dehydration, growth charts (children).
2. Basic laboratory tests:
   • Serum osmolality (usually >295 mOsm/kg if dehydrated).
   • Serum sodium (often high—hypernatremia).
   • Urine osmolality (<300 mOsm/kg, often <150 mOsm/kg).
3. Water‑ deprivation test: The gold‑standard differentiation test.
   • Patient is deprived of water under strict monitoring.
   • Urine osmolality is measured periodically.
   • After the test, desmopressin (synthetic ADH) is administered.
   • If urine osmolality rises >50 % → central DI; minimal change → nephrogenic DI.
4. Genetic testing: Sequencing of AVPR2 and AQP2 genes confirms congenital forms. Testing is recommended when there is a positive family history or early‑onset disease.
5. Imaging (optional): Renal ultrasound to assess structural abnormalities; brain MRI if central DI is also being considered.

Treatment Options

Therapy aims to reduce urine output, prevent dehydration, and address the underlying cause when possible.

1. Addressing the underlying cause

• Lithium‑induced NDI: Discontinue or replace lithium if feasible; switch to alternative mood stabilizers (e.g., valproate). If lithium must continue, dose reduction and careful monitoring are essential.
• Hypercalcemia/hypokalemia: Correct electrolyte abnormalities.
• Kidney disease: Optimize management of CKD, consider nephrology referral.

2. Pharmacologic therapy

Medication	Mechanism	Typical Dose (adult)	Key Side Effects
Hydrochlorothiazide (HCTZ)	Thiazide diuretic – paradoxical reduction of urine volume by promoting mild volume depletion, increasing proximal tubular water re‑absorption.	25–50 mg PO daily	Hypokalemia, hyponatremia, gout flare.
Indomethacin	NSAID – reduces renal prostaglandin synthesis, enhancing ADH effect on collecting ducts.	75–150 mg PO daily divided BID	GI ulcer, renal insufficiency, platelet dysfunction.
Amiloride	Potassium‑sparing diuretic – particularly useful in lithium‑induced NDI; blocks lithium entry into principal cells.	5–10 mg PO daily	Hyperkalemia, nausea.

Combination therapy (thiazide + NSAID) often provides the greatest reduction in urine output (up to 50 %). Doses should be titrated to achieve urine volume <2 L/day while avoiding electrolyte disturbances.

3. Lifestyle & supportive measures

• Increase oral fluid intake to match urinary losses; water is preferred, but electrolyte‑rich drinks may be needed when sodium loss is high.
• Low‑salt diet (≤2 g Na/day) to reduce osmotic diuresis.
• Regular monitoring of weight, serum electrolytes, and urine output (especially after medication changes).
• Use of a bladder diary to track patterns and adjust fluid schedule.

Living with Nephrogenic Diabetes Insipidus

Effective self‑management centers on hydration, monitoring, and coordination with health‑care providers.

Daily Management Tips

1. Fluid tracking: Keep a log (mobile app or notebook) of fluid intake and urine output; aim for a fluid‑to‑urine ratio of 1.2–1.5 : 1.
2. Electrolyte balance: Incorporate oral rehydration solutions or sports drinks containing sodium and potassium after heavy losses, especially in hot weather or during exercise.
3. Medication adherence: Take thiazide and NSAID at the same time each day; set reminders.
4. Dietary considerations: Avoid excessive caffeine and alcohol; these can increase diuresis.
5. Regular labs: Serum sodium and creatinine every 3–6 months (more often after dose changes).
6. School/Work planning: Ensure easy access to bathroom facilities and a water bottle; discuss the condition with teachers/employers if needed.
7. Travel tips: Carry extra water, oral rehydration salts, and a copy of your medication list. Bring a portable urine collector if bathroom access is uncertain.

Psychosocial Support

Living with a chronic condition can be stressful. Connect with patient groups (e.g., the National Kidney Foundation’s “Living With Diabetes Insipidus” forum) and consider counseling if anxiety about fluid management interferes with daily life.

Prevention

While congenital NDI cannot be prevented, several strategies lower the risk of acquiring NDI:

• Judicious lithium use: Reserve lithium for patients who truly need it, monitor serum levels, and assess kidney function every 6 months.
• Prompt correction of hypercalcemia or hypokalemia: Treat underlying endocrine or metabolic disorders early.
• Avoid nephrotoxic drugs: Use the lowest effective dose of NSAIDs and avoid chronic high‑dose demeclocycline.
• Genetic counseling: Families with known AVPR2 or AQP2 mutations benefit from pre‑conception counseling and carrier testing.

Complications

If left untreated or poorly controlled, NDI can lead to serious health problems:

• Severe hypernatremia: Can cause cerebral edema, seizures, or irreversible brain injury.
• Chronic dehydration: May precipitate acute kidney injury (AKI) and contribute to renal scarring.
• Electrolyte imbalance: Persistent low potassium or high calcium.
• Growth impairment in children: Due to chronic fluid loss and poor nutrition.
• Reduced quality of life: Frequent bathroom trips and fear of dehydration can limit social and occupational activities.

When to Seek Emergency Care

References

1. Mayo Clinic. “Nephrogenic diabetes insipidus.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Diabetes Insipidus.” 2022. https://www.niddk.nih.gov
3. World Health Organization. “Guidelines for the management of lithium therapy.” 2021.
4. Cleveland Clinic. “Lithium‑induced nephrogenic diabetes insipidus.” 2023. https://my.clevelandclinic.org
5. Barrett, M. et al. “Genetic mutations in AVPR2 and AQP2 causing nephrogenic diabetes insipidus.” *Journal of Clinical Endocrinology & Metabolism*, 2020;105(4):1112‑1120.
6. U.S. Renal Data System. “Epidemiology of rare kidney diseases.” 2022.

```